Omega-3 Polyunsaturated Fatty Acids Suppress the Cystic Lesion Formation of Peritoneal Endometriosis in Transgenic Mouse Models

Kensuke Tomio¹, Kei Kawana¹*, Ayumi Taguchi², Yosuke Isobe², Ryo Iwamoto², Aki Yamashita¹, Satoko Kojima¹, Mayuyo Mori¹, Takeshi Nagamatsu¹, Takahide Arimoto¹, Katsutoshi Oda¹, Yutaka Osuga¹, Yuji Taketani¹, Jing X. Kang², Hiroyuki Ara³, Makoto Arita³*, Shiro Kozuma¹, Tomoyuki Fujii¹

¹Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ³Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

Abstract
Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) play a role in controlling pathological inflammatory reactions. Endometriosis is characterized by the presence of endometrial tissue on the peritoneum and an exaggerated inflammatory environment around ectopic tissues. Here peritoneal endometriosis was reproduced using a mouse model in which murine endometrial fragments were inoculated into the peritoneal cavity of mice. Fat-1 mice, in which omega-6 can be converted to omega-3 PUFAs, or wild type mice, in which it cannot, were used for the endometriosis model to address the actions of omega-3 PUFAs on the development of endometriotic lesions. The number and weight of cystic endometriotic lesions in fat-1 mice two weeks after inoculation were significantly less than half to those of controls. Mediator lipidomics revealed that cystic endometriotic lesions and peritoneal fluids were abundant in 12/15-hydroxyeicosapentaenoic acid (12/15-HEPE), derived from eicosapentaenoic acid (EPA), and their amount in fat-1 mice was significantly larger than that in controls. 12/15-Lipoxygenase (12/15-LOX)-knockout (KO) and control mice with or without EPA administration were assessed for the endometriosis model. EPA administration decreased the number of lesions in controls but not in 12/15-LOX-KO mice. The peritoneal fluids in EPA-fed 12/15-LOX-KO mice contained reduced levels of EPA metabolites such as 12/15-HEPE and EPA-derived resolvins E3 even after EPA administration. cDNA microarrays of endometriotic lesions revealed that interleukin-6 (IL-6) expression in fat-1 mice was significantly lower than that in controls. These results suggest that both endogenous and exogenous EPA-derived PUFAs protect against the development of endometriosis through their anti-inflammatory effects and, in particular, the 12/15-LOX-pathway products of EPA may be key mediators to suppress endometriosis.

Introduction
Eicosapentaenoic acid (EPA, C20:5n-3) and Docosahexaenoic acid (DHA, C22:6n-3) are representative omega-3 polyunsaturated fatty acids (PUFAs) and show anti-inflammatory effects in acute and chronic inflammatory conditions [1]. Increased levels of omega-3 PUFAs in a tissue lead to the formation of functional EPA or DHA-derived mediators, such as resolvins and protectins, and protects from tissue damage [2]. Many studies have been focused on their effect in resolving inflammation mostly through reductions in neutrophil trafficking and upregulation of macrophage-mediated removal of apoptotic cells [3]. This is associated with attenuated pro-inflammatory signaling by Leukotriene B4 Receptor 1 (BLT1) and ChemR23, which are expressed on neutrophils and macrophages [4,5], respectively, and decreased activity of the pro-inflammatory transcription factor nuclear factor kappa beta (NF-κB) [6,7].

Dietary supplementation is a traditional approach to modify tissue nutrient composition in animal studies of nutrition. Feeding animals different diets that consist of many components derived from different materials can cause many variations between experimental groups. Kang et al. recently engineered a transgenic mouse that carries the fat-1 gene from the roundworm Caenorhabditis elegans [8]. This gene encodes an omega-3 fatty acid desaturase that catalyzes conversion of omega-6 to omega-3 PUFAs and that is absent in most animals, including mammals. There is a remarkable difference in the tissue omega-6/omega-3 PUFAs ratio between wild type and fat-1 transgenic mice [9]. Fat-1
Omega-3 Fatty Acids Suppress Endometriosis

Omega-3 fatty acids (PUFAs) have been shown to have anti-inflammatory effects, and their potential role in endometriosis has been investigated. However, the role of omega-3 PUFAs in endometriosis remains unclear.

To address this, we hypothesized that omega-3 PUFAs could suppress the development of endometriotic lesions in a mouse model. We established a model of endometriosis in mice using a heterologous approach, in which endometrial fragments were inoculated into the peritoneum of mice. We then evaluated the effects of omega-3 PUFAs on the development of endometriotic lesions.

Materials and Methods

Animals and Diets

Fat-1 mice were created on a C57BL/6 background and heterozygote as described [9] and subsequently backcrossed (at least four times) onto a C57BL/6 background. 12/15-LOX-KO mice on a C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME). Animals were fed a special diet (AIN-76A+10% safflower oil; CLEA Japan, Inc.) that contained 10.3% total fat with fatty acid composition of C16:0 (7.6%), C18:0 (2.7%), C18:1n-9 (14.1%), C18:2n-6 (73.2%), C18: 3n-3 (0.3%), C20:4n-6 (<0.1%), C20:5n-3 (<0.1%), C22: 6n-3 (<0.1%), high in n-6 and low in n-3 fatty acids, until the desired age (6–8 weeks) for experiments. EPA was administered by the addition of 5% EPA ethyl ester (kindly provided by Mochida Pharmaceutical Co., Ltd., Japan) in the fish meal-free F1 diet (Funabashi farm Co., Ltd., Japan) that contained 4.4% total fat with fatty acid composition of C16:0 (14.9%), C18:0 (5.0%), C18:1n-9 (20.8%), C18:2n-6 (52.4%), C18:3n-3 (4.9%), C20:4n-6 (<0.1%), C20:5n-3 (<0.1%), C22: 6n-3 (<0.1%). To prevent the oxidation of lipids, all diet was stored in the refrigerator with antioxidants (AGELESS; Mitsubishi Gas Chemical Inc.), and prepared newly every two days. Animal studies were approved by the University of Tokyo Animal Committee.

Endometriosis model in mice

Both donor and recipient mice, 6–8 weeks old, were ovariec-
tomized to remove the effects of endogenous hormonal changes. All donor mice and recipient mice were injected s.c. with 100 µg/kg estradiol depot (ASKA Pharmaceutical Co., Ltd., Tokyo, Japan) in corn oil every week from the time of the ovariectomy. Two weeks after the ovariectomy, donor mice were killed by cervical dislocation. Uterine horns were removed and put into a dish containing phosphate-buffered saline (PBS). Endometrial fragments, obtained by peeling off the serosa and myometrium gently, were minced using a razor blade. Fragments suspended in 0.6 ml PBS were injected with an 18-gauge needle through the abdominal wall just below the umbilicus into the peritoneal cavity of recipient mice with a ratio of one donor to two recipients. Fat-1, 12/15-LOX-KO, or littermate wild type mice were used as both donor and recipient mice for each group. Five mice for each group were sacrificed two weeks after the injection and peritoneal endometriotic lesions and peritoneal washes were collected.

Evaluation of peritoneal lesions

Peritoneal lesions forming a cystic lesion were covered with surrounding stromal cells histologically, backed by endometrial cells, and showed much more at the omentum, pelvic cavity, mesenterium and diaphragm. After counting the number of cystic lesions, they were completely excised, fixed with 2% Paraformaldehyde (PFA) + PBS (WAKO, Osaka, Japan), and embedded in paraffin. Serial sections were cut at 8 µm thickness on a cryostat and mounted on poly-L-lysine-treated slides. They were stained with hematoxylin-eosin (HE) and observed under microscopy (BX50: Olympus, Japan). The histological diagnosis of endometriosis was based on the morphological identification of endometriotic glands and stroma. The weight of endometriotic lesions was measured.
Lipid mediator analyses
LC-MS/MS-based mediator lipidomics was performed as described previously [26]. Briefly, samples were extracted by solid-phase extraction using Sep-Pak C18 cartridges (Waters, Milford, MA, USA) with deuterium-labeled internal standards (PGE2-d4, LTB4-d4, 15-HETE-d8, arachidonic acid-d8). LC-MS/MS-based lipidomic analyses were performed on Acquity UPLC BEH C18 column (1.0 mm x 150 mm x 1.7 μm) using Acquity UltraPerformance LC system (Waters Co.) coupled to an electrospray (ESI) triple quadrupole mass spectrometer (QTRAP5500; AB SCIEX). The MS/MS analyses were performed in negative ion mode, and the eicosanoids and docosanoids were identified and quantified by multiple reaction monitoring. Calibration curves between 1 and 1000 pg and the LC retention times for each compound were constructed with synthetic standards.

cDNA Microarray
We collected cystic lesions 2 weeks after injection of minced endometrium, and total RNA was extracted from their lesions. They were incubated in RNA later. For the cDNA microarray analysis, 0.5 μg of pooled total RNA was amplified and labeled using an Amino Allyl MessageAmpTM II aRNA Amplification kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Each sample of aRNA labeled with Cy3 and reference aRNA labeled with Cy5 was cohybridized with GeneTM Mouse Oligo chip 24 k (Toray Industries Inc., Tokyo, Japan) at 37°C for 16 h. After hybridization, each DNA chip was washed and dried. Hybridization signals derived from Cy3 and Cy5 were scanned using Scan Array Express (PerkinElmer, Waltham, MA, USA). The scanned image was analyzed using GenePix Pro (MDS Analytical Technologies, Sunnyvale, CA, USA). All analyzed data were scaled by global normalization.

RT-PCR for peritoneal macrophages
After washing the peritoneal cavity of each mouse with 5 ml PBS, peritoneal washes were filtered through a 0.22 μm strainer and centrifuged for 5 min at 200 g. From recovered cellular components, CD11b-positive macrophages were isolated using an isolation kit and incubated in RNA later. We isolated RNA from these macrophages after homogenizing. Two μg of total RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden, Germany), followed by reverse transcription. We amplified cDNA for 40 cycles with a Light Cycler 480 (Roche, Basel, Switzerland) using a Universal Probe Master and the following primers and Universal Probe Library UPL probes (Roche): Interleukin-6 (IL-6) Forward (gacctcaacgtcttaccaa) and Reverse (ccaggtctcatgacttacggag), with the UPL Probe #6 and β-actin (ACTB) Forward (ctgaagcctcaagggaaatatg) and Reverse (ccaggtctcatgacttacggag), with the UPL Probe #64. We calculated expression levels by the comparative CT method using β-actin as an endogenous reference gene.

Statistical Analysis
Results were expressed as mean ± standard error. Comparisons between the two groups were performed using the Mann-Whitney U test. Comparisons between multigroups were performed using the Tukey-Kramer post hoc multiple comparisons test.

Results
Comparison of endometriotic lesions between fat-1 and wild type mice
Fat-1 and littermate wild type mice were fed with a diet enriched in omega-6 PUFAs. Omega-6 PUFAs are converted into omega-3 PUFAs by fat-1. C. elegans n-3 fatty acid desaturase, in fat-1 mice. The high omega-6 diet led to wide differences in fatty acid profiles, i.e. low (fat-1) vs. high (wild type) omega-6/omega-3 ratios in a litter of mice born to the same mother. We then generated the homologous endometriosis model in which the uterus of fat-1 or wild type mice was minced and injected into the peritoneal cavity of fat-1 or wild type mice, respectively. The AA/EPA + DHA ratio of uterine tissues from the fat-1 mice was 0.02 and from the wild type mice was 2.14. Endometrial fragments were incubated in the peritoneal cavity of mice for two weeks with estrogen treatment. After incubation, mice were sacrificed and the whole peritoneal cavity was examined carefully. Both fat-1 and wild type mice had a scattering of approximately 2–3 mm of cystic mass on the peritoneum. The number of cystic lesions was counted macroscopically and the cystic mass was resected separately for evaluation of the weight. A comparison was made for the number and weight of endometriotic lesions between fat-1 and wild type mice (n = 10 in each group) (Fig. 1). The cystic mass, composed of monolayer columnar epithelia and endometrial stroma, was histologically diagnosed as an endometrial cyst (data not shown). In fat-1 mice, the number of lesions was fewer than half and the weight per lesion was less than half that of wild type mice, indicating that the development of cystic endometriotic lesions were dramatically reduced in fat-1 mice.

Lipidomics of endometriotic lesions in fat-1 and wild type mice
Fat-1 mice showed a decreased number and weight of cystic endometriotic lesions suggesting that increased omega-3 PUFAs are associated with the suppression of endometriosis. To address the mechanisms involved in this suppressive effect, LC-MS/MS-based lipidomic analyses were performed to monitor lipid mediators derived from omega-3 as well as omega-6 PUFAs [26]. First, the endometriotic lesion was examined by lipidomic analyses and a direct comparison was made for PUFAs metabolites between fat-1 and wild type mice (n = 3 in each group) (Fig. 2). A

Figure 1. Development of endometriotic lesions in fat-1 and wild type mice. A cystic mass was histologically confirmed as an endometriotic lesion. (A) The number of lesions was counted macroscopically. (B) All masses were resected. The weight (mg) per lesion was measured. These data were compared between the fat-1 and wild type (WT) mice (n = 10 in each group). Mean values with standard deviations are presented. Asterisks indicate those comparisons (fat-1 vs. wild type mice) with statistical significance (p<0.05). doi:10.1371/journal.pone.0073085.g001
whole series of EPA metabolite was significantly increased in fat-1 mice compared to the wild type. Among the EPA metabolites, most difference in 12/15-hydroxyicosapentaenoic acids (HEPE) levels was observed (Fig. 2). As for DHA, there was no metabolite showing a significant difference between fat-1 and wild type mice (Fig. 2). In contrast, AA metabolites in fat-1 mice were generally lower than those in the wild type mice (Fig. 2). Next, peritoneal exudates were collected from the endometriosis-present peritoneal cavity of fat-1 or wild type mice and were assessed for PUFA metabolite profiles. Again, there was no difference in the amounts of DHA metabolites between fat-1 and wild type mice (data not shown). The main products derived from EPA and AA in peritoneal cavity were shown in Fig. 3. Peritoneal fluids were abundant in 12/15-HEPE in EPA metabolites and 12/15-hydroxyeicosatetraenoic acids (HETE) in AA metabolites. The amounts of 12/15-HEPE in fat-1 mice were significantly greater than that in wild type mice, as shown in endometriotic lesions (Fig. 3, center panel). Among AA metabolites, a significant difference in the amounts of 12/15-HETE between fat-1 and wild type mice was shown (Fig. 3, upper panel). These were the same findings as those shown in endometriotic lesions. Taken together, the increased amount of 12/15-HEPE was characterized markedly in both the endometriotic lesions and peritoneal cells of fat-1 mice.

Endometriosis in the 12/15-LOX-KO mice

EPA-derived 12/15-HEPE was higher and AA-derived 12/15-HETE was lower in the endometriotic lesions of fat-1 mice than those in wild type mice. Since both 12/15-HEPE and 12/15-HETE are converted by 12/15-LOX, 12/15-LOX-related mediators may play a role in protection against the development of peritoneal endometriotic lesions. Then 12/15-LOX-KO and wild type mice were administrated EPA orally to address the effect of 12/15-LOX-related mediators on endometriotic lesions by comparing the number of the lesions with that of wild type mice. Endometriotic lesions were generated in wild type and 12/15-LOX-KO mice with or without EPA administration (n = 4 in each group) (Fig. 4). EPA administration decreased significantly the number of endometriotic lesions in wild type mice. However, the suppressive effect by EPA administration on the development of endometriotic lesions was cancelled in 12/15-LOX-KO mice. In 12/15-LOX-KO mice with or without EPA administration, the number of endometriotic lesions was the same level as that of wild type mice with no administration.

Then we examined amounts of lipid mediators derived from omega-3 as well as omega-6 PUFAs in the peritoneal fluids obtained from wild type and 12/15-LOX-KO mice with or without EPA administration (n = 3 in each group) (Fig. 5). In wild
type mice with EPA administration, all EPA metabolites were significantly increased compared with wild type mice without EPA administration. In comparison between wild type and 12/15-LOX-KO mice with EPA administration, 12/15-HEPE was significantly decreased in 12/15-LOX KO mice while PGE3 and 5-HEPE were almost equal amount between wild type and 12/15-LOX-KO mice. Interestingly, EPA-derived bioactive mediators, 18S/R-resolvin E3 (RvE3) which is biosynthesized from 18-HEPE by 12/15-LOX [27], was increased in peritoneal fluids of wild type mice after EPA administration (Fig. 5, center panel). Again, the increase of RvE3 was canceled in 12/15-LOX-KO mice. The other E-series resolvins, RvE1 and RvE2, were negligible amounts in both mice (data not shown). As for AA metabolites, there was no difference in amounts of AA metabolites between wild type and 12/15-LOX-KO mice after EPA administration.

Comparison of expression profiles in endometriotic lesions between fat-1 and wild type mice

In humans, the symptoms of endometriosis are thought to result from an excessive inflammatory environment within the peritoneal cavity. Elevated numbers of activated immune cells, including macrophages, are involved in the production of inflammatory cytokines. The expression profiles of endometriotic lesions in our mice model were assessed using cDNA microarrays. A comparison was made between the fat-1 and wild type mice for IL-6 mRNA expression in peritoneal macrophages (n = 5 in each group) (Fig. 6). IL-6 mRNA production in macrophages in fat-1 mice was significantly suppressed by approximately one fifth that of wild type mice.

Suppression of IL-6 mRNA production in peritoneal macrophages in fat-1 mice

Peritoneal macrophages are one of the most important immune cells to play a role in the development and progression of endometriosis in the peritoneal cavity. Interestingly, peritoneal macrophages possess 12/15-LOX abundantly and, in turn, 12/15-LOX expressing cells are predominantly macrophages in the peritoneal cavity in mice, while circulating and myeloid monocytes do not express 12/15-LOX. We focused on peritoneal macrophages as a source of IL-6 and isolated macrophages from the peritoneal cavity of fat-1 and wild type mice by CD11b-positive selection. A comparison was made between the fat-1 and wild type mice for IL-6 mRNA expression in peritoneal macrophages (n = 5 in each group) (Fig. 6). IL-6 mRNA production in macrophages in fat-1 mice was significantly suppressed by approximately one fifth that of wild type mice.

Discussion

Numerous studies utilize fat-1 mice to examine the effects of omega-3 PUFAs and the resultant anti-inflammatory mediators on retarding inflammatory disease development and/or progression to cancer. These models include LPS-induced hepatitis, dextrane sodium sulfate (DSS)-induced colitis, and chronic colitis-associated colon cancer [28–30]. Because it is possible to collect and analyze peritoneal fluid, modified mice are particularly suitable for...
intraperitoneal diseases. We find fat-1 mice very suitable as models of endometriosis, because endometriosis is an intraperitoneal disease. Fat-1 mice allow carefully controlled studies to be performed in the absence of potential confounding factors of diet. Here, fat-1 mice allowed us to investigate essential endogenously biosynthesized mediators to suppress endometriotic lesions.

In this mouse model used in our experiment, cystic lesions were formed as endometriotic lesions macroscopically. By counting the number of them, and then excised them from surrounding normal tissues, we could evaluate the suppressive effects on lesion formation. In the results of this study, we could observe a significant difference on lesion formation at the macroscopic level. But some problems still remain. We could not evaluate and excise exactly small and invisible lesions to the naked eye. For example, it is sometimes difficult to distinguish small non-cystic lesions and microscopic lesions from surrounding normal tissues. As a solution, an animal model using green fluorescence protein (GFP) mice may be useful in order to evaluate the small non-cystic lesions and microscopic lesions from surrounding normal tissues. A central effect on the development of endometriotic lesions, consistent with the results of a previous study [31]. This suggested EPA and/or any EPA-derived mediators exhibit suppressive effect on the endometriotic lesions. In wild type mice, EPA administration protected against the development of endometriotic lesions, consistent with the results of a previous study [31]. This suggested EPA and/or any EPA-derived mediators exhibit suppressive effect on the endometriotic lesions in fat-1 mice. Interestingly, the suppressive effect was canceled in 12/15-LOX-KO mice although the mice were administered EPA, suggesting that EPA itself may not have a central effect on the development of endometriotic lesion. Our lipid mediator analyses demonstrated that amounts of 12/15-HEPE amounts were observed similarly in both endometriotic lesions and peritoneal exudates. This allowed us to focus on 12/15-LOX-related mediator as a possible lipid mediator to suppress endometriosis; 12/15-LOX-KO mice were then utilized to address their suppressive effect on peritoneal endometriotic lesions. In wild type mice, EPA administration protected against the development of endometriotic lesions, consistent with the results of a previous study [31]. This suggested EPA and/or any EPA-derived mediators exhibit suppressive effect on the endometriotic lesions in fat-1 mice. Interestingly, the suppressive effect was canceled in 12/15-LOX-KO mice although the mice were administered EPA, suggesting that EPA itself may not have a central effect on the development of endometriotic lesion. Our lipid mediator analyses demonstrated that amounts of 12/15-LOX-related metabolites such as 12/15-HEPE and RVE3 in wild type mice were much larger than those in 12/15-LOX-KO mice after EPA administration. RVE3 is recently identified as a novel EPA-derived anti-inflammatory bioactive mediator which is biosynthesized from 18-HEPE via 12/15-LOX pathway [27]. Taken together, endometriotic lesions seem to be suppressed in a manner dependent on 12/15-LOX pathway. EPA-derived 12/15-LOX-related mediators may play a role in the protection effect in this model.

Interestingly, more than 95% of murine peritoneal macrophages express 12/15-LOX [35]. In turn, the predominant population expressing 12/15-LOX is resident peritoneal macrophages in mice [36]. Peritoneal macrophages are increased in number and more activated in patients with endometriosis [37,38] and are one of the major sources for inflammatory cytokines in the peritoneal cavity. Therefore, peritoneal macrophages are thought to be involved in

Figure 4. Comparison of the number of endometriotic lesions between wild type and 12/15-LOX-KO mice with or without EPA administration. Endometriotic lesions were generated in wild type (WT: black) and 12/15-LOX-KO (stripe) mice with or without oral administration of 5% EPA ethyl ester. The number of endometriotic lesions was compared between the wild type and 12/15-LOX-KO mice with or without EPA oral administration (n = 4 in each group). Mean values with standard deviations are presented. Asterisks indicate those comparisons with statistical significance (p<0.05).

doi:10.1371/journal.pone.0073085.g004
the development of endometriosis. The increased amounts of 12/15-LOX-related EPA metabolites in the peritoneal exudates of fat-1 mice may originate from peritoneal macrophages enriched in omega-3 PUFA. The anti-inflammatory effect of EPA metabolites may inhibit the development of peritoneal endometriotic lesions. The decreased IL-6 mRNA levels in the peritoneal cells of fat-1 mice seem to reflect anti-inflammatory actions. One study demonstrated that there were 1.7-fold more peritoneal macrophages in 12/15-LOX-KO mice than that in wild type mice and

**Figure 5.** Lipid mediator analyses of peritoneal fluids from wild type or 12/15-LOX-KO mice with or without EPA administration. Peritoneal exudates of mice developing endometriotic lesions were collected by washing with saline. The peritoneal fluids obtained from mice as shown in Fig. 5 were analyzed for lipid mediators (n = 3 in each group). The main products of AA-, EPA- and DHA-derived mediators were indicated. Y axis denotes the amount of each lipid mediator (pg/g sample). Mean values with standard deviations are presented. Asterisks indicate those comparisons (wild type vs. 12/15-LOX-KO mice) with significance (p < 0.05).

doi:10.1371/journal.pone.0073085.g005

**Table 1.** Comparison of the cytokine/chemokine profiles of peritoneal endometriotic lesions between fat-1 and wild type (WT) mice (n = 3 in each group).

| Cytokines | fat-1/WT ratio |
|-----------|----------------|
| IL-6      | 0.2            |
| TNF-α     | 0.6            |
| TGF-β1    | 0.8            |
| TGF-β2    | 0.6            |
| IL-1b     | 0.7            |
| IL-4      | 0.5            |
| IL-10     | 0.5            |
| IL-12b    | 1.0            |
| IL-17a    | 0.9            |

doi:10.1371/journal.pone.0073085.t001

**Figure 6.** IL-6 production of peritoneal macrophages derived from fat-1 and wild type mice. Peritoneal fluids were collected from the fat-1 (white) and wild type (WT: black) mice as shown in Fig. 4 (n = 5 in each group). Among them, peritoneal macrophages were isolated by CD11b-beads selection. IL-6 mRNA levels in isolated macrophages were measured by RT-quantitative PCR. IL-6 mRNA levels were normalized to β-actin. Mean values with standard deviations are presented. Asterisks indicate those comparisons (fat-1 vs. wild type mice) with statistical significance (p < 0.05).

doi:10.1371/journal.pone.0073085.g006
that the 12/15-LOX pathway exerted negative effects on monocyte/macrophage migration into the peritoneal cavity [39]. This decrease may be favorable for protection against the development of endometriotic lesions in 12/15-LOX-KO mice.

In this study, we showed the suppressive effect of omega-3 PUFAs in the mouse endometriosis model by making full use of two types of genetically modified mice: fat-1 and 12/15-LOX KO. To take sufficient amounts of omega-3 PUFAs, we need to eat a lot of fish and fish oil or EPA supplements. However, there are limitations to the amount of sufficient omega-3 PUFAs intake, so we think it is desirable that we identify more effective metabolites than omega-3 PUFAs themselves. We revealed the function of key metabolites in the suppressive mechanism by using lipidomic analysis. Further research will provide more insight into the effects of omega-3 PUFAs and possibly lead to the treatment for endometriosis involving novel anti-inflammatory mediators.

Acknowledgments

We gratefully thank Ms. Michiko Kamio for technical assistance on LC-MS/MS analyses, and Dr. Yutaka Takazawa for excellent comments concerning the histological study of endometriotic lesions.

Author Contributions

Conceived and designed the experiments: KT KK YI MA YO YT S. Koizuma TF. Performed the experiments: KT KK YI RI HA MA. Analyzed the data: KT KK YI RI HA MA. Contributed reagents/materials/analysis tools: KT KK AT AY S. Kojima MM TN TA KO. Wrote the paper: KT KK YO MA.

References

1. Seki H, Sasaki T, Ueda T, Arita M (2010) Resolvins as regulators of the immune system. ScientificWorldJournal 10: 818–831.
2. Marcheselli VL, Hong S, Lukov WJ, Tian XH, Gronert K, et al. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278: 43807–43817.
3. Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869–874.
4. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, et al. (2005) Stereocellular assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713–722.
5. Arita M, Ohira T, Sun VP, Elangovan S, Chiang N, et al. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178: 3912–3917.
6. Kure I, Nishimiya S, Nishitani Y, Tanoue T, Ishida T, et al. (2010) Lipoxin A4 selectively blocks lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. J Pharmacol Exp Ther 332: 541–548.
7. Seki H, Fukunaga K, Arita M, Aran H, Nakanishi H, et al. (2010) The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 184: 836–843.
8. Kang JX (2007) Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids 77: 263–267.
9. Kang JX, Wang J, Wu L, Kang ZB (2004) Transgenic mice fat-1 mouse convert n-6 to n-3 fatty acids. Nature 427: 504.
10. Giudice LC (2010) Clinical practice. Endometriosis. N Engl J Med 362: 2389–2398.
11. Giudice LC, Kao LC (2004) Endometriosis. Lancet 364: 1789–1799.
12. Buyalos RP, Funari VA, Azizi R, Watson JM, Martinez-Maza O (1992) Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Fertil Steril 58: 302–306.
13. Iscove T, Harada T, Tzao T, Nagano Y, Yoshida S, et al. (2000) Tumor necrosis factor-alpha promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J Clin Endocrinol Metab 85: 824–829.
14. Takatani Y, Kiso TM, Mizuno M (1992) Comparison of cytokines and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis. Am J Obstet Gynecol 167: 265–270.
15. Ohuha Y, Kogo K, Hiraoka Y, Hiraata T, Yoshiho O, et al. (2011) Lipidocytes in endometriosis. Am J Reprod Immunol 65: 1–16.
16. de Ziegler D, Borchese B, Chapron C (2010) Endometriosis and infertility: pathophysiology and management. Lancet 376: 730–738.
17. Arici A (2002) Local cytokines in endometrial tissue: the role of interleukin-8 in the pathogenesis of endometriosis. Ann N Y Acad Sci 955: 101–109; discussion 118, 396–406.
18. Van Langendonckt A, Casanas-Roux F, Donnez J (2002) Iron overload in the pathogenesis of endometriosis. Am J Obstet Gynecol 187: 1160–1167.
19. Covens AL, Christopher P, Casper RF (1988) The effect of dietary supplementation with fish oil fatty acids on surgically induced endometriosis in the rabbit. Fertil Steril 49: 689–703.
20. Hirata T, Ohaga Y, Yoshino O, Hirota Y, Harada M, et al. (2005) Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod 20: 2092–2096.
21. Story L, Kennedy S (2004) Animal studies in endometriosis: a review. ILAR J 45: 132–138.
22. Tirado-Gonzalez I, Barrientos G, Tarverrivan N, Arck PC, Garcia MG, et al. (2010) Endometriosis research: animal models for the study of a complex disease. J Reprod Immunol 86: 141–147.
23. Vernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44: 684–694.
24. Awwad JT, Sayegh RA, Tao XJ, Hassan T, Awad SL, et al. (1999) The SCID mouse: an experimental model for endometriosis. J Reprod Immunol 14: 3107–3111.
25. Arita M (2012) Mediator lipidomics in acute inflammation and resolution. J Biochem 152: 313–319.
26. Joehe Y, Arita M, Matsueda S, Isacomo R, Fujihara T, et al. (2012) Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyicosapentaenoic acid. J Biol Chem 287: 10525–10534.
27. Huddert CA, Weylant VL, Lu Y, Wang J, Hong S, et al. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A 103: 11276–11281.
28. Nowak J, Weylant KH, Habbel P, Wang J, Dignass A, et al. (2007) Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 28: 1991–1995.
29. Schmocker C, Weylant KH, Kahle L, Wang J, Loheck H, et al. (2007) Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology 45: 864–869.
30. Neta S, Komori R, Odaigri K, Soma M, Fujisawa H, et al. (2008) Oral eicosapentaenoic acid supplementation as possible therapy for endometriosis. Fertil Steril 90: 1496–1502.
31. Gazvani MR, Smith L, Haggarty P, Fowler PA, Templeton A (2001) High omega-3: omega-6 fatty acid ratios in culture medium reduce endometrial-cell survival in combined endometrial gland and stromal cells cultures from women with and without endometriosis. Fertil Steril 76: 717–722.
32. Gonzalez-Ramos R, Van Langendonckt A, Deffere S, Louise JC, Colette S, et al. (2010) Involvement of the nuclear factor-kappaB pathway in the pathogenesis of endometriosis. Fertil Steril 94: 1983–1994.
33. Nau K, Nishida M, Ueda T, Yuge A, Takai N, et al. (2007) Application of the nuclear factor-kappaB inhibitor BAY 11–7083 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab 293: E16–E23.
34. Kuhn H, O’Donnell VB (2006) Inflammation and immune regulation by 12/15-lipoxygenase. Current Top Microb Immunol 293: 1–22.
35. Kuhn H, O’Donnell VB (2006) Inflammation and immune regulation by 12/15-lipoxygenase. Current Top Microb Immunol 293: 1–22.
36. Lebovic DI, Mueller MD, Taylor RN (2004) Immunobiology of endometriosis. Fertil Steril 75: 1–10.
37. Montagut P, Capellino S, Villaggio B, Remorgida V, Ragna N, et al. (2008) Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril 90: 156–164.
38. D’Onofrio G, Solis A, Machado RL, Schindler P, Tarres BL, et al. (2008) 12/15-Lipoxygenase regulates the inflammatory response to bacterial products in vivo. J Immunol 181: 6514–6524.